Business Daily Media

Business Marketing

.

Singapore eDevelopment (SGX:40V) biomedical subsidiary confirms LB2 efficacy against Ebola

  • Written by ACN Newswire

Singapore eDevelopment (SGX:40V) biomedical subsidiary confirms LB2 efficacy against Ebola

SINGAPORE, Mar 1, 2018 - (ACN Newswire) - Singapore eDevelopment (SGX: 40V; SeD) is pleased to announce biomedical subsidiary Global BioLife, Inc. has completed the initial Zaire Ebola research portion for the study of new anti-viral drug LB2, part of its new universal therapeutic drug platform, Linebacker, which is designed to combat a range of...

Popular

Pluralsight to Help Machine Learning Enthusiasts Skill Up with AWS DeepRacer

Pluralsight, Inc. (NASDAQ: PS), the technology skills and engineering management platform, today announced a collaboration with Amazon Web Services (AWS) that will help technologists enhance their machine learning (ML) skill...

AUSTRALIAN BUSINESS LEADERS CALL ON EMPLOYERS TO OFFER PAID VACCINATION LEAVE

Lendi Group (Aussie and Lendi brands), Domain Group, Prospa, Zip Co, Honey Insurance, Athena and Valiant Finance today announced paid vaccination leave for all permanent employees and are calling on the wider Australian busine...

Vistaprint Partners with Artists to Release Re-usable Face Masks

Vistaprint, the marketing partner to small businesses, brings its first artist capsule collection of face masks to the Australian market. The launch is part of Vistaprint’s global efforts to normalise mask-wearing whilst, ce...